Abstract | INTRODUCTION: The aim is to conduct an updated systematic review comparing palonosetron to other 5-HT3RAs for the prophylaxis of CINV, assess for publication biases, and determine whether further RCTs are required, that could potentially lead to a different meta-conclusion. METHODS: Random-effects analysis model was used to generate odds ratio (OR), risk differences (RD) and accompanying 95% confidence intervals (CI). Funnel plots to assess for biases and cumulative meta-analyses to assess effect size over time were generated. RESULTS: 4145 patients were randomized to palonosetron and 4911 received other 5-HT3RAs. In the majority of efficacy endpoints, the meta-conclusion has not changed over time - recent clinical trials simply narrow CIs the meta-conclusion. Safety profile boasts a stable conclusion over time. No publication biases exist. CONCLUSION: Considering the vast amount of resources needed to conduct RCTs, resources should be dedicated to other prophylactic treatments/settings which have not been as well explored.
|
Authors | Ronald Chow, Matti Aapro, Rudolph M Navari, Richard Gralla, Nicholas Chiu, Leonard Chiu, Stephanie Chan, Marko Popovic, Henry Lam, Michael Lock, Carlo DeAngelis |
Journal | Critical reviews in oncology/hematology
(Crit Rev Oncol Hematol)
Vol. 142
Pg. 164-186
(Oct 2019)
ISSN: 1879-0461 [Electronic] Netherlands |
PMID | 31419719
(Publication Type: Comparative Study, Journal Article, Meta-Analysis)
|
Copyright | Copyright © 2019. Published by Elsevier B.V. |
Chemical References |
- Antiemetics
- Antineoplastic Agents
- Serotonin 5-HT3 Receptor Antagonists
- Palonosetron
|
Topics |
- Antiemetics
(therapeutic use)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Humans
- Nausea
(chemically induced, prevention & control)
- Neoplasms
(drug therapy)
- Odds Ratio
- Palonosetron
(therapeutic use)
- Serotonin 5-HT3 Receptor Antagonists
(therapeutic use)
- Vomiting
(chemically induced, prevention & control)
|